Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 6-7, 2006, Pages 497-505

  Bernfort, Lars ^a   Sennfält, Karin ^a   Reichard, Olle ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SWEDEN; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MARKOV CHAINS; MONTE CARLO METHOD; QUALITY OF LIFE; RIBAVIRIN; SWEDEN;

EID: 33746595252     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540500532803     Document Type: Article

References (25)

1. Alter, MJ and Kruszon-Moran, D and Nainan, OV and McQuillan, GM and Gao, F and Moyer, LA and (1999) The prevalence of hepatitis C virus infection in the United States, 1988 to 1994 N Engl J Med, 341, pp. 566-62.
2. Nguyen, MH and Keeffe, EB. (2004) Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9. Rev Gastroent Dis, 4(Suppl 1), pp. S14-21.
3. Socialstyrelsen, Hälso- och sjukvårdsstatistisk årsbok 2002 [Yearbook of Health and Medical Care 2002]. 2002; Stockholm: Socialstyrelsen.
4. Wong, JB and McQuillan, GM and McHutchison, JG and Poynard, T. (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health, 90, pp. 1562-9.
5. Poynard, T and Marcellin, P and Lee, SS and Niederau, C and Minuk, GS and Ideo, G and (1998) Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. Lancet, 352, pp. 1426-32.
6. Sennfält, K and Reichard, O and Hultkrantz, R and Wong, JB and Jonsson, D. (2001) Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scan J Gastroenterol, 36, pp. 870-6.
7. Manns, MP and McHutchison, JG and Gordon, SC and Rustgi, VK and Shiffman, M and Reindollar, R and (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial Lancet, 358, pp. 958-65.
8. Davis, GL and Wong, JB and McHutchison, JG and Manns, MP and Harvey, J and Albrecht, J. (2003) Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38, pp. 645-52.
9. ReichardO, NorkransG, FrydenA, BraconierJH, Sönnerborg A, Weiland O and the Swedish Study Group. Randomized, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
10. Bennett, WG and Inoue, Y and Beck, R and Wong, JB and Pauker, SG and Davis, GL. (1997) Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med, 127, pp. 855-65.
11. Christensen, E and Krintel, J and Hansen, S and Johansen, J and Juhl, E. (1989) Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors. Scand J Gastroenterol, 24, pp. 999-1006.
12. Graffeo, M and Buffoli, F and Lanzani, G and Donato, F and Cesari, P and Benedini, D and (1994) Survival after endoscopic sclerotherapy for oesophageal varices in cirrhotics. Am J Gastroenterol, 89, pp. 1815-22.
13. Takahashi, M and Yamada, G and Miyamoto, R and Doi, T and Endo, H and Tsuji, T. (1993) Natural course of chronic hepatitis C. Am J Gastroenterol, 88, pp. 240-3.
14. Tsukuma, H and Hiyama, T and Tanaka, S and Nakao, M and Yabuuchi, T and Kitamura, T and (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med, 328, pp. 1797-801.
15. Gane, EJ and Portmann, BC and Naoumov, NV and Smith, HM and Underhill, JA and Donaldson, PT and (1996) Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med, 334, pp. 815-20.
16. Yano, M and Kumada, H and Kage, M and Ikeda, K and Shimamatsu, K and Inoue, O and (1996) The long-term pathological evolution of chronic hepatitis C. Hepatology, 23, pp. 1334-40.
17. Fattovich, G and Giustina, G and Degos, F and Tremolada, F and Diodati, G and Almasio, P and (1997) Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology, 112, pp. 463-72.
18. Dore, GJ and Freeman, AJ and Law, M and Kaldor, JM. (2002) Is severe liver disease a common outcome for people with chronic hepatitis C? Journal of Gastroenterology and Hepatology, 17, pp. 423-30.
19. Dore, GJ and Freeman, AJ and Law, M and Kaldor, JM. (2003) Natural history models for hepatitis C-related liver disease: Different disease progression parameters for different settings. Antiviral Therapy, 8, pp. 365-72.
20. Weinstein, MC and Siegel, JE and Gold, MR and Kamlet, MS and Russel, LB. (1996) Recommendations of the panel on cost-effectiveness in health and medicine. JAMA, 276, pp. 1253-8.
21. Siebert, U and Sroczynski, G and Rossol, S and Wasem, J and Ravens-Sieberer, U and Kurth, BM and (2003) German hepatitis C model (GEHMO) group, international hepatitis interventional therapy (IHIT) group. Cost effectiveness of peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut, 52, pp. 425-32.
22. Wong, J and Poynard, T and Ling, M-H and Albrecht, JK and Pauker, SG. (2000) Cost-effectiveness of 24 or 48 weeks of interferon alfa-2b alone or with ribavirin as initial treatment of chronic hepatitis. Am J Gastroenterol, 95, pp. 1524-30.
23. Buti, M and Medina, M and Casado, MA and Wong, JB and Fosbrook, L and Esteban, R. (2003) A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther, 17, pp. 687-94.
24. Zeuzem, S and Hultcrantz, R and Bourliere, M and Goeser, T and Marcellin, P and Sanches-Tapias, J and (2004) Peg-interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol, 40, pp. 993-9.
25. Deuffic-Burban, S and Wong, JB and Valleron, A-J and Costagliola, D and Delfraissy, J-F and Poynard, T. (2004) Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol, 40, pp. 319-26.